A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Use of syringes not intended for semaglutide contributes to the variability of dosing units (milliliters ... Seeing 'Morbidly Obese' on Her Chart 'Shook' Her, So This Grandma Decided to Lose ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient ... administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...